FDA grants full approval for remdesivir as COVID-19 treatment in young kids
In this April 25, 2022 article for The Hill, Peter Sullivan reports that the US Food and Drug Administration (FDA) has granted full approval for remdesivir as a COVID-19 treatment for children under 12 years.
The approval covers children who are 28 days and older and who weigh at least 3 kilograms and are either hospitalized or at high risk of severe illness
Editor’s Note: What data did the FDA use to approve the use of remdesivir on kids?
Based on the evidence, remdesivir has been pretty damaging among adults [see New study: WHO data shows Remdesevir causes serious bradycardia among COVID-19 patients, WHO advises against use of remdesevir for COVID patients, Dr. Bryan Ardis: Remdesivir is the Real Cause of COVID Deaths].
How did the FDA determine that remdesivir would do better among children? [Also read WHO study shows remdesivir offers no benefit to COVID-19 patients].
To understand the dangers of remdesivir’s approval for children, we encourage you to watch this morning’s newscast by the Children’s Health Defense. [You might also want to read this letter to Dr. Malone: An Open Letter to Doctor Robert Malone (Inventor of mRNA biotechnology)].
Read Original Article
Click the button below if you wish to read the article on the website where it was originally published.
Click the button below if you wish to read the article offline.